Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.40 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.40 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 3/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27686606 | 0.96 | CA12 (0.48) | CA12CA1CA2CA9MCL1 | |
| SCHEMBL28830541 | 0.96 | CA12 (0.48) | CA12CA1CA2CA9MCL1 | |
| SCHEMBL27571439 | 0.94 | CA12 (0.43) | CA12CA1CA2CA9MCL1 | |
| SCHEMBL29212556 | 0.92 | CA12 (0.42) | CA12CA1CA2CA9MCL1 | |
| SCHEMBL27902263 | 0.92 | CA12 (0.42) | CA12CA1CA2CA9MCL1 | |
| Water SCHEMBL8948779 | 0.82 | ESR2 (0.52) | CA12CA1CA2CA9MCL1 | |
| SCHEMBL2750748 | 0.82 | PDCD1 (0.38) | CA12CA1CA2CA9TSHR | |
| SCHEMBL29551674 | 0.82 | CA12 (0.61) | CA12CA1CA2CA9MCL1 | |
| SCHEMBL3633054 | 0.82 | CA12 (0.61) | CA12CA1CA2CA9MCL1 | |
| SCHEMBL1836912 | 0.79 | MAPK1 (0.36) | TSHRNPC1RAB9ASMN1; SMN2NISCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115724785-A | Method for asymmetric catalytic synthesis of 3,3-disubstituted chiral indolone derivative | 重庆医科大学 | 2023-03-03 | — | — | CN | claimed |
| US-20230052586-A1 | DISUBSTITUTED ALKYNE DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-02-16 | — | — | US | claimed |
| EP-3898588-B1 | DISUBSTITUTED ALKYNE DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-01-11 | — | — | EP | claimed |
| CN-115385956-A | Biaryl diphosphine ligands and transition metal complexes thereof | 东莞市均成高新材料有限公司 | 2022-11-25 | — | — | CN | claimed |
| EP-2160187-B1 | SPIROINDALONES | MERCK SHARP & DOHME (US) | 2013-05-22 | — | — | EP | claimed |
| US-8309544-B2 | Spiroindalones | MERCK SHARP & DOHME CORP. (US) | 2012-11-13 | — | — | US | claimed |
| US-20110136050-A1 | ELECTROPHOTOGRAPHIC PHOTOCONDUCTOR AND IMAGE FORMING APPARATUS INCLUDING THE SAME | SHARP KABUSHIKI KAISHA (JP) | 2011-06-09 | — | — | US | claimed |
| US-20110076602-A1 | ELECTROPHOTOGRAPHIC PHOTOCONDUCTOR AND IMAGE FORMING APPARATUS INCLUDING THE SAME | SHARP KABUSHIKI KAISHA (JP) | 2011-03-31 | — | — | US | claimed |
| US-20100137297-A1 | SPIROINDALONES | MERCK SHARP & DOHME LLC | 2010-06-03 | — | — | US | claimed |
| CN-101678011-A | Spiro-indolinone compounds | MERCK & CO INC | 2010-03-24 | — | — | CN | claimed |
| US-6962942-B2 | Azacycloalkanone serine protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2005-11-08 | — | — | US | claimed |
| EP-1525185-A1 | ACETYLAMINO BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC Therapeutics, Inc. (US) | 2005-04-27 | — | — | EP | claimed |
| WO-2004009533-A1 | ACETYLAMINO BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS, INC. (US) | 2004-01-29 | — | — | WO | claimed |
| EP-1212300-B1 | AZACYCLOALKANONE SERINE PROTEASE INHIBITORS | DIMENSIONAL PHARM INC (US) | 2003-11-05 | — | — | EP | claimed |
| US-20030109517-A1 | Azacycloalkanone serine protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-06-12 | — | — | US | claimed |
| US-6521667-B1 | Calcilytic compounds | NPS PHARMACEUTICALS, INC. | 2003-02-18 | — | — | US | claimed |
| US-6469029-B1 | INHIBITORS OF THROMBIN PRODUCTION VIA FACTOR XA INHIBITION; COUPLED TO MEDICAL DEVICES, SUCH AS STENTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-10-22 | — | — | US | claimed |
| CN-1362464-A | Organic electroluminescent material | UNIV QINGHUA (CN) | 2002-08-07 | — | — | CN | claimed |
| EP-1212300-A1 | AZACYCLOALKANONE SERINE PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2002-06-12 | — | — | EP | claimed |
| WO-2001019795-A1 | AZACYCLOALKANONE SERINE PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-03-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230052586-A1 | DISUBSTITUTED ALKYNE DERIVATIVES | BRCA1, MYC, PCNA | CA12 4730/4885CA1 4883/4885CA2 4672/4885 |
| US-20100137297-A1 | SPIROINDALONES | HIF1AN, HIF1A, EGLN2 | CA12 3141/4885CA1 2823/4885CA2 680/4885 |
| US-20030109517-A1 | Azacycloalkanone serine protease inhibitors | CTRL, SERPINE1, SERPINB1 | CA12 3887/4885CA1 1358/4885CA2 3511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.